Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis

BACKGROUND: Ocrelizumab is a monoclonal antibody targeting CD20-expressing B cells used in the treatment of multiple sclerosis (MS). Currently, there is limited safety data in pregnancy. OBJECTIVES: To report the pregnancy outcome following exposure to ocrelizumab in MS. METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, Shin Yee, Kermode, Allan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905230/
https://www.ncbi.nlm.nih.gov/pubmed/35284087
http://dx.doi.org/10.1177/20552173221085737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905230/
https://www.ncbi.nlm.nih.gov/pubmed/35284087
http://dx.doi.org/10.1177/20552173221085737

Ejemplares similares